Clostridioides Difficile Infections - Epidemiology Forecast - 2034
Description
Key Highlight
The total incident cases of CDI in the 7MM ranged from 610,800 in 2020, at a CAGR of –0.4% during the study period (2020–2034).
CDI is a serious gastrointestinal condition caused by toxin-producing C. difficile bacteria, often linked to antibiotic use and healthcare settings. It can present as either HA-CDI or Community-associated CDI (CA-CDI), ranging from mild diarrhea to life-threatening colitis. CDI remains a significant public health concern due to its high recurrence and healthcare burden.
Initially, a predominantly healthcare-acquired infection, CDI has increasingly been detected in community settings, including among younger, otherwise healthy individuals and peripartum women. Community-associated cases now make up a growing proportion of the overall CDI burden.
Over the past decade, healthcare-associated CDI incidence and mortality have declined, attributed to enhanced infection prevention, reduced use of high-risk antibiotics (notably fluoroquinolones), and targeted stewardship initiatives. The prevalence of the hypervirulent ribotype 027 strain has also declined, though it remains a significant cause of healthcare-associated CDI.
There are significant gaps in the epidemiological data of CDI in Japan, and CDI is frequently underdiagnosed in the country despite its clinical relevance.
Recurrence is a common challenge in CDI, with approximately 20–30% of patients experiencing a recurrence after initial treatment.
DelveInsight’s ‘CDI – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain), and the United Kingdom
Japan
Study Period: 2020–2034
CDI Disease Understanding and Treatment Algorithm
Clostridioides difficile Infection (CDI) Overview
Clostridioides difficile, formerly clostridium difficile, is a gram-positive and spore-forming bacterium. This obligate anaerobic bacillus is recognized for its ability to produce toxins and is the leading cause of antibiotic-associated diarrhea worldwide. CDIs can range from an asymptomatic carrier to diarrhea, progressing to severe conditions such as pseudomembranous colitis and toxic megacolon with septic shock, often resulting in a high mortality rate.
Clostridioides difficile Infection (CDI) Diagnosis
CDI diagnosis is primarily clinical but should be supported by laboratory tests and, when necessary, imaging and endoscopic findings. A prompt diagnosis is crucial both for correct patient management and implementation of infection control measures, especially in healthcare settings.
Stool examination
Imaging
Endoscopy
Histologic features
Biomarkers
Further details related to diagnosis and treatment are provided in the report…
CDI Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident cases of CDI, type-specific incident cases of CDI, gender-specific incident cases of CDI, severity-specific incident cases of CDI, age-specific incident cases of CDI, and CDI treated, recurrent, and mortality patient pool in the 7MM market covering the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
The epidemiology segment also provides the CDI epidemiology data and findings across the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The total incident population of CDI in the 7MM comprised nearly 610,800 cases in 2024 and is projected to increase during the forecast period.
The total incident cases of CDI in the US were nearly 380,000 in 2024.
The US contributed the largest prevalent population of CDI, accounting for ~62% of the 7MM in 2024.
In EU4 and the UK, the incident cases of CDI were found to be maximum in Germany, followed by France. While the least number of cases were found in Spain in 2024.
In 2024, the incident cases of mild to moderate CDI in the US were identified to be ~76%, and severe as ~24%.
In Japan, nearly 67% of CDI cases accounted for the age group 65 years and above, and ~33% cases were below 65 years in 2024.
CDI was predominantly a HA-CDI, especially affecting older adults and those with recent antibiotic exposure or hospitalization. However, there is a growing recognition of CA-CDI, which now constitutes a significant portion of cases. Community cases often involve younger, previously healthy individuals, although severe outcomes remain more common in older or immunocompromised patients.
Scope of the Report
The report covers a segment of an executive summary and a descriptive overview of CDI, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
A detailed review of the CDI epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
A detailed review of current challenges in establishing the diagnosis.
CDI Report Insights
Patient population
Country-wise epidemiology distribution
CDI Report Key Strengths
10-year forecast
7MM coverage
CDI epidemiology segmentation
CDI Report Assessment
Epidemiology segmentation
Current diagnostic practices
Key Questions
FAQs
What are the patient burden trends of Clostridioides difficile infection (CDI) in the seven major markets? Historically, healthcare-acquired Clostridium difficile infection (HA-CDI cases have declined in the United States. What other major markets are showing similar HA-CDI patient burden trends?
CDI is associated with significant mortality, particularly among elderly and immunocompromised patients. Each not only raises the chance of another recurrence but also increases the mortality risk. What are the mortality rates (%) in the 7MM after each recurrence episode?
What are the disease risk, burden, and unmet needs of CDI? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CDI?
What is the historical CDI patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What would be the forecasted patient pool of CDI at the 7MM level?
Out of the countries mentioned above, which country would have the highest prevalent population of CDI during the study period (2020–2034)?
At what CAGR is the population expected to grow across the 7MM during the study period (2020–2034)?
Reasons to Buy
The report will help in developing business strategies by understanding trends shaping and driving the CDI market.
To understand the future market competition in the CDI market, an insightful review of the key market drivers and barriers.
Quantify patient populations in the global CDI market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for CDI in the US, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
The CDI Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and highlights disease trends over a 10-year forecast period using reputable sources.
The total incident cases of CDI in the 7MM ranged from 610,800 in 2020, at a CAGR of –0.4% during the study period (2020–2034).
CDI is a serious gastrointestinal condition caused by toxin-producing C. difficile bacteria, often linked to antibiotic use and healthcare settings. It can present as either HA-CDI or Community-associated CDI (CA-CDI), ranging from mild diarrhea to life-threatening colitis. CDI remains a significant public health concern due to its high recurrence and healthcare burden.
Initially, a predominantly healthcare-acquired infection, CDI has increasingly been detected in community settings, including among younger, otherwise healthy individuals and peripartum women. Community-associated cases now make up a growing proportion of the overall CDI burden.
Over the past decade, healthcare-associated CDI incidence and mortality have declined, attributed to enhanced infection prevention, reduced use of high-risk antibiotics (notably fluoroquinolones), and targeted stewardship initiatives. The prevalence of the hypervirulent ribotype 027 strain has also declined, though it remains a significant cause of healthcare-associated CDI.
There are significant gaps in the epidemiological data of CDI in Japan, and CDI is frequently underdiagnosed in the country despite its clinical relevance.
Recurrence is a common challenge in CDI, with approximately 20–30% of patients experiencing a recurrence after initial treatment.
DelveInsight’s ‘CDI – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain), and the United Kingdom
Japan
Study Period: 2020–2034
CDI Disease Understanding and Treatment Algorithm
Clostridioides difficile Infection (CDI) Overview
Clostridioides difficile, formerly clostridium difficile, is a gram-positive and spore-forming bacterium. This obligate anaerobic bacillus is recognized for its ability to produce toxins and is the leading cause of antibiotic-associated diarrhea worldwide. CDIs can range from an asymptomatic carrier to diarrhea, progressing to severe conditions such as pseudomembranous colitis and toxic megacolon with septic shock, often resulting in a high mortality rate.
Clostridioides difficile Infection (CDI) Diagnosis
CDI diagnosis is primarily clinical but should be supported by laboratory tests and, when necessary, imaging and endoscopic findings. A prompt diagnosis is crucial both for correct patient management and implementation of infection control measures, especially in healthcare settings.
Stool examination
Imaging
Endoscopy
Histologic features
Biomarkers
Further details related to diagnosis and treatment are provided in the report…
CDI Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident cases of CDI, type-specific incident cases of CDI, gender-specific incident cases of CDI, severity-specific incident cases of CDI, age-specific incident cases of CDI, and CDI treated, recurrent, and mortality patient pool in the 7MM market covering the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
The epidemiology segment also provides the CDI epidemiology data and findings across the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The total incident population of CDI in the 7MM comprised nearly 610,800 cases in 2024 and is projected to increase during the forecast period.
The total incident cases of CDI in the US were nearly 380,000 in 2024.
The US contributed the largest prevalent population of CDI, accounting for ~62% of the 7MM in 2024.
In EU4 and the UK, the incident cases of CDI were found to be maximum in Germany, followed by France. While the least number of cases were found in Spain in 2024.
In 2024, the incident cases of mild to moderate CDI in the US were identified to be ~76%, and severe as ~24%.
In Japan, nearly 67% of CDI cases accounted for the age group 65 years and above, and ~33% cases were below 65 years in 2024.
CDI was predominantly a HA-CDI, especially affecting older adults and those with recent antibiotic exposure or hospitalization. However, there is a growing recognition of CA-CDI, which now constitutes a significant portion of cases. Community cases often involve younger, previously healthy individuals, although severe outcomes remain more common in older or immunocompromised patients.
Scope of the Report
The report covers a segment of an executive summary and a descriptive overview of CDI, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
A detailed review of the CDI epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
A detailed review of current challenges in establishing the diagnosis.
CDI Report Insights
Patient population
Country-wise epidemiology distribution
CDI Report Key Strengths
10-year forecast
7MM coverage
CDI epidemiology segmentation
CDI Report Assessment
Epidemiology segmentation
Current diagnostic practices
Key Questions
FAQs
What are the patient burden trends of Clostridioides difficile infection (CDI) in the seven major markets? Historically, healthcare-acquired Clostridium difficile infection (HA-CDI cases have declined in the United States. What other major markets are showing similar HA-CDI patient burden trends?
CDI is associated with significant mortality, particularly among elderly and immunocompromised patients. Each not only raises the chance of another recurrence but also increases the mortality risk. What are the mortality rates (%) in the 7MM after each recurrence episode?
What are the disease risk, burden, and unmet needs of CDI? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CDI?
What is the historical CDI patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What would be the forecasted patient pool of CDI at the 7MM level?
Out of the countries mentioned above, which country would have the highest prevalent population of CDI during the study period (2020–2034)?
At what CAGR is the population expected to grow across the 7MM during the study period (2020–2034)?
Reasons to Buy
The report will help in developing business strategies by understanding trends shaping and driving the CDI market.
To understand the future market competition in the CDI market, an insightful review of the key market drivers and barriers.
Quantify patient populations in the global CDI market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for CDI in the US, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
The CDI Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and highlights disease trends over a 10-year forecast period using reputable sources.
Table of Contents
96 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary
- 4. Epidemiology Forecast Methodology
- 5. CDI Market Overview at a Glance
- 5.1. Patient Share (%) Distribution of CDI in 2020
- 5.2. Patient Share (%) Distribution of CDI in 2034
- 6. Disease Background and CDI
- 6.1. Introduction to CDI
- 6.2. Symptoms Associated With CDI
- 6.3. Causes
- 6.4. Risk Factors
- 6.5. Pathophysiology of CDI
- 6.5.1. Pathogenic Factors
- 6.6. Clinical Manifestations
- 6.7. Infection Prevention and Control
- 6.8. Diagnosis
- 6.8.1. Diagnostic algorithm
- 7. Epidemiology and Patient Population
- 7.1. Key Findings
- 7.2. Assumptions and Rationale: The 7MM
- 7.3. Total Population at Risk of Developing CDI in the 7MM
- 7.4. Total Incident Cases of CDI in the 7MM
- 7.5. The United States
- 7.5.1. Incident Cases of CDI in the US by Type (HA-CDI and CA-CDI)
- 7.5.2. Gender-specific Incident Cases of CDI in the US
- 7.5.3. Severity-specific Incident Cases of CDI in the US
- 7.5.4. Age-specific Incident Cases of CDI in the US
- 7.5.5. CDI Treated, Recurrent, and Mortality Patient Pool in the US
- 7.6. EU4 and the UK
- 7.6.1. Incident Cases of CDI in EU4 and the UK by Type (HA-CDI and CA-CDI)
- 7.6.2. Gender-specific Incident Cases of CDI in EU4 and the UK
- 7.6.3. Severity-specific Incident Cases of CDI in EU4 and the UK
- 7.6.4. Age-specific Incident Cases of CDI in EU4 and the UK
- 7.6.5. CDI Treated, Recurrent, and Mortality Patient Pool in EU4 and the UK
- 7.7. Japan
- 7.7.1. Incident Cases of CDI in Japan by Type (HA-CDI and CA-CDI)
- 7.7.2. Gender-specific Incident Cases of CDI in Japan
- 7.7.3. Severity-specific Incident Cases of CDI in Japan
- 7.7.4. Age-specific Incident Cases of CDI in Japan
- 7.7.5. CDI Treated, Recurrent, and Mortality Patient Pool in Japan
- 8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
- 9. DelveInsight Capabilities
- 10. Disclaimer
- 11. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
